Use of antagonists of the CBI receptor for the manufacture of a composition useful for the treatment of hepatic diseases

US8604060B2 · kind B2 · utility

Assignees

• INSERM · FR
• Sanofi · FR

Inventors

• Sophie Lotersztajn · Paris, FR
• Ariane Mallat · Paris, FR
• Pascale Grenard · Briançon, FR
• Boris Julien · Paris, FR
• Jeanne V. Nhieu · Saint-Maur-des-Fossés, FR

Key dates

• Filing date: Jun 28, 2012
• Grant date: Dec 10, 2013
• Expiry date: Jun 28, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the use of antagonists to the CB1 receptor for the preparation of a composition for the treatment of hepatic diseases and preferably to the use of N-piperidino5 5-(4-chlorophenyl)-1-(2, 4-dichloropenyl)-4-methylpyrazole-3-carboxamide.